Larry Allen, MD: Personalizing Current and Future Heart Failure Therapies

Video

The University of Colorado expert joins for a 5-part interview on making sense of the boom of new agents and care strategies.

The field of heart failure (HF) therapy is nearly unrecognizable to that of almost one decade ago. Successive findings in cardiovascular safety and benefit from SGLT-2 inhibitor therapies—including for in-need patients with preserved ejection fraction (HFpEF)—was behind a boom in available complementary and leading therapies for HF. While the field is still growing, clinicians are in need of updated guidance on how all the newly availble—and possibly future—agents fit into their care plans.

Larry Allen, MD, Medical Director, Heart Failure, University of Colorado Anschutz School of Medicine, recently spoke on the individualized care plan for patients with heart failure at Beaumont Health's 30th Annual Cardiovascular Conference at Beaver Creek.

The leading clinician joined HCPLive Managing Editor Kevin Kunzmann for a 5-part extended discussion on individualizing heart failure treatment. Key topics included context on the pivotal trials supporting new drugs; prescribing strategies and navigating costs with patients; potential FDA approvals for new agents this year; needs in HFpEF treatment; and the latest organization guidelines for care.

Navigate the playlist above to listen to Allen's perspective on everything heart failure treatment.

Recent Videos
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
Brendon Neuen, MBBS, PhD | Credit: X.com
Viability of Elamipretide for Geographic Atrophy in Dry AMD | Image Credit: HCPLive
Advancing Elamipretide into Phase 3 ReNEW and ReGAIN Trials | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.